Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis: A prospective, controlled pilot study
References (34)
- et al.
Rates of cancellous bone remodelling and turnover in osteopenia associated with primary biliary cirrhosis
Bone
(1993) - et al.
A controlled trial of prednisolone treatment in primary biliary cirrhosis; three year results
J Hepatol
(1992) - et al.
Four-year study of intermittent cyclic etidronate treatment of post-menopausal osteoporosis: three years of blinded therapy followed by one year of open therapy
Am J Med
(1993) - et al.
Prevention of steroid induced osteoporosis with (3-amino-1-hydroxypropylididene)-,1-bisphosphonate (APD)
Lancet
(1988) - et al.
Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women
Am J Med
(1995) - et al.
Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis
Am J Med
(1995) - et al.
Glucocorticoid-induced osteoporosis
Clin Rheum Dis
(1986) Primary biliary cirrhosis and bone disease
Hepatology
(1995)- et al.
Bone mass in women with primary biliary cirrhosis; the relation with histological stage and use of corticosteroids
Gastroenterology
(1990) - et al.
Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy
Gastroenterology
(1985)
Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference
Hepatology
Interpreting trials of bone-active agents
Am J Med
Bone loss in response to long term glucocorticoid therapy
Bone Miner
Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis
Hepatology
Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis
Neth J Med
A randomized, placebo-controlled trial with prednisone/azathioprine in addition to ursodeoxycholic acid in primary biliary cirrhosis [Abstract]
J Hepatol
Cited by (122)
The Impact of Tenofovir Disoproxil Fumarate on Reduced Bone Mineral Density and Fractures in Liver Transplant Recipients
2021, Transplantation ProceedingsCitation Excerpt :Despite the obvious differences in the etiology of liver disease in prior studies, it is also important to note that these studies covered a different era in transplantation regarding immunosuppression and other medications. Differences in rates of fractures may also be explained by the adoption of bisphosphonate therapy as standard of care for osteoporosis by the beginning of our study period [30–32]. We selected a control group consisting of LT recipients with viral hepatitis not taking TDF that included patients with HCV.
Glucocorticoid-induced osteoporosis and Cushing’s syndrome
2020, Marcus and Feldman’s OsteoporosisEASL Clinical Practice Guidelines on nutrition in chronic liver disease
2019, Journal of HepatologyGlucocorticoid-Induced Osteoporosis
2013, Osteoporosis: Fourth EditionOsteoporosis in liver cirrhosis
2012, Gastroenterologia y HepatologiaThe Pharmacologic Management of Osteoporosis in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis
2020, Journal of Clinical DensitometryCitation Excerpt :We included RCTs of bisphosphonates or hormone replacement therapy (HRT) separately and analyzed different generations of bisphosphonates both together and separately. The 2 studies evaluating etidronate (5,13) were considered “first generation bisphosphonates” while the one study evaluating alendronate (14) was considered a “third generation bisphosphonate.” For our primary outcome of fracture risk, only the etidronate study by Lindor et al (5) and the alendronate study by Zein et al (14) were able to be pooled as there were no events in either arm of the etidronate study by Wolfhagen et al (13) or the HRT study by Ormarsdottir et al (15).